Impact of aki in patients with cirrhotic liver and received hcv treatment
Background and Aims: Egypt had controlled liver cirrhosis who received HCV vaccine in line to modulate its impact among nephrotic patients. Current clinical trial aim to investigate acute kidney injury (AKI) impact among liver cirrhosis individuals who received HCV treatment. Material and methods: A prospective, multi-center clinical trial, on 50 liver cirrhosis patients who eligible to receive HCV treatment.